Directional headlamp assembly
    4.
    发明授权

    公开(公告)号:US11440460B1

    公开(公告)日:2022-09-13

    申请号:US17361481

    申请日:2021-06-29

    申请人: Brian Spencer

    发明人: Brian Spencer

    IPC分类号: B60Q1/076 F21S41/657 B60Q1/00

    摘要: A directional headlamp assembly for independently directing light from a pair of headlamps includes a pair of headlamp modules and a controller. Each headlamp module replaces a respective headlamp of a pair of existing headlamps of a vehicle. The headlamp module comprises a first housing, which insertable of into an opening created upon removal of the respective headlamp, so that the first housing is engaged to the vehicle. A bulb is pivotally engaged to a front of the first housing. An actuator is engaged to and positioned in the first housing. The actuator is operationally engaged to the bulb. The controller is mountable within a passenger compartment of the vehicle so that it is accessible to a driver of the vehicle. The controller is independently and operationally engaged to each of the actuators and thus is positioned to selectively actuate each actuator to direct light emitted by an associated bulb.

    Compounds for reversing and inhibiting protein aggregation, and methods for making and using them
    7.
    发明授权
    Compounds for reversing and inhibiting protein aggregation, and methods for making and using them 有权
    用于逆转和抑制蛋白质聚集的化合物,以及制备和使用它们的方法

    公开(公告)号:US08946165B2

    公开(公告)日:2015-02-03

    申请号:US13119400

    申请日:2009-09-29

    IPC分类号: A61K38/00 C07K14/47 C07K19/00

    摘要: The invention provides compositions for increasing the clearance of protein aggregates, and pharmaceutical compositions comprising them, and methods for making and using them, including methods for accelerating protein aggregate clearance in the CNS, e.g., for treating diseases that are characterized by protein aggregation—including some degenerative neurological diseases such as Parkinson's disease. In one aspect, the compositions of the invention specifically target synuclein, beta-amyloid and/or tau protein aggregates, and the methods of the invention can be used to specifically prevent, reverse, slow or inhibit synuclein, beta-amyloid and/or tau protein aggregation. In alternative embodiments, the compositions and methods of the invention, are used to treat, prevent, reverse (partially or completely) or ameliorate (including slowing the progression of) degenerative neurological diseases related to or caused by protein aggregation, e.g., synuclein, beta-amyloid and/or tau protein aggregation. In one aspect, compositions and methods of this invention are used to treat, prevent or ameliorate (including slowing the progression of) Parkinson's disease, fronto-temporal dementia (FTD), Alzheimer's Disease (AD), Lewy body disease (LBD) and Multiple system atrophy (MSA).

    摘要翻译: 本发明提供了用于增加蛋白质聚集体清除率的组合物,以及包含它们的药物组合物,以及用于制备和使用它们的方法,包括用于加速CNS中的蛋白质聚集体清除的方法,例如用于治疗以蛋白质聚集为特征的疾病 一些退行性神经系统疾病如帕金森病。 在一个方面,本发明的组合物特异性靶向突触核蛋白,β-淀粉样蛋白和/或tau蛋白聚集体,并且本发明的方法可用于特异性地预防,逆转,减缓或抑制突触核蛋白,β-淀粉样蛋白和/或tau 蛋白质聚集。 在替代实施方案中,本发明的组合物和方法用于治疗,预防,逆转(部分或完全)或改善(包括减缓进展)与蛋白质聚集相关或由其引起的退行性神经疾病,例如突触核蛋白,β - 淀粉样蛋白和/或tau蛋白聚集。 一方面,本发明的组合物和方法用于治疗,预防或改善(包括减缓帕金森氏病,颞叶性痴呆(FTD),阿尔茨海默病(AD),路易体病(LBD)和多发性硬化症 系统萎缩(MSA)。